证券代码：688322 证券简称：奥比中光 奥比中光科技集团股份有限公司 2025 年度向特定对象发行 A 股股票 募集资金使用可行性分析报告 （修订稿） （本报告中如无特别说明，相关用语具有与《奥比中光科技集团股份有限公司 2025 年度向特定对象发行 A 股股票预案（修订稿）》中的释义相同的含义） 二〇二五年九月 在不改变本次募集资金拟投资项目的前提下，经公司股东会授权，董事会可以对上 述单个或多个投资项目的募集资金投入金额进行调整。若本次发行扣除发行费用后的实 际募集资金少于上述项目募集资金拟投入总额，公司可以根据实际募集资金净额，按照 项目的轻重缓急等情况，调整募集资金投入的优先顺序及各项目的具体投资额等使用安 排，募集资金不足部分由公司自筹解决。本次发行募集资金到位之前，公司可以根据募 投项目实际进度情况以自有资金或自筹资金先行投入，待募集资金到位后按照相关规定 程序予以置换。 二、项目方案概述及可行性分析 （一）机器人AI视觉与空间感知技术研发平台项目 一、本次募集资金使用计划 为进一步增强公司综合竞争力，根据公司发展需要，公司拟向特定对象发行 A 股 股票募集资金总额不超过人民币 191,844 ...

证券代码：688322 证券简称：奥比中光 公告编号：2025-067 奥比中光科技集团股份有限公司 第二届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 奥比中光科技集团股份有限公司（以下简称"公司"）第二届董事会第十八次会 议通知于 2025 年 9 月 9 日以电话、电子邮件等方式向全体董事、高级管理人员发出， 会议于 2025 年 9 月 12 日在公司会议室以现场结合通讯表决方式召开。本次会议由公 司董事长黄源浩先生主持，会议应出席董事 10 名，实际出席董事 10 名（其中 4 名董 事以通讯表决方式出席会议），公司全体高级管理人员列席本次会议。本次会议的召 集、召开及表决程序符合《中华人民共和国公司法》（以下简称"《公司法》"）等法律、 行政法规、规范性文件和《奥比中光科技集团股份有限公司章程》的规定，合法有效。 二、董事会会议审议情况 （一）会议以 10 票同意，0 票反对，0 票弃权，审议通过了《关于调整公司<2025 年度向特定对象发行 A 股股票方案 ...

Group 1 - The company has adjusted its plan for issuing A-shares to specific investors for the year 2025, with a maximum issuance of 120 million shares [1] - The total amount of funds to be raised is capped at 1.918 billion yuan, including the principal amount [1] - The raised funds will be allocated to the development of a robotics AI vision and spatial perception technology platform, the construction of an AI vision sensor and smart hardware manufacturing base, and to supplement working capital [1]

Group 1 - The core viewpoint highlights the strong performance of the domestic AI industry, with the Sci-Tech Innovation AI ETF (589520) experiencing a significant intraday increase of 4.27% and a current rise of 2.91%, indicating active trading with a real-time transaction amount exceeding 430 million yuan [1] - Key stocks within the ETF, such as Cambricon, Yuntian Lifei, and Xinghuan Technology, have shown substantial gains, with Cambricon rising over 9% and others increasing by more than 6% [1] - OpenAI has signed a $300 billion agreement with Oracle for computing power over five years, leading to a 36% surge in Oracle's stock price, which resulted in a market capitalization increase of approximately $250 billion in a single day [3] Group 2 - The domestic computing power industry is experiencing significant growth, with the number of standard racks in use reaching 10.85 million and the intelligent computing power scale reaching 788 EFLOPS as of June this year [3] - The urgency for domestic computing power replacement is increasing due to U.S. restrictions on advanced chip exports to China, emphasizing the need for independent design and production of high-end AI chips in China [3] - The recent policy document on implementing the "Artificial Intelligence +" initiative is expected to catalyze the industrialization of AI, with a focus on hardware-software collaboration and the establishment of AI infrastructure [4] Group 3 - The Sci-Tech Innovation AI ETF (589520) has undergone a share split, reducing the trading threshold from approximately 120 yuan to about 60 yuan, making it more accessible for investors [4] - The ETF is positioned to benefit from the rapid advancement of AI technology, with a focus on domestic alternatives and information security amid ongoing technological tensions [5] - The top ten holdings of the ETF account for over 71.66% of its weight, with the semiconductor sector representing more than 54.1%, indicating a concentrated and aggressive investment strategy [5]

Group 1 - The stock price of Aobo Zhiguang increased by 2.02% on September 11, reaching 86.38 yuan per share, with a trading volume of 275 million yuan and a turnover rate of 1.11%, resulting in a total market capitalization of 34.647 billion yuan [1] - Year-to-date, Aobo Zhiguang's stock price has risen by 85.76%, with a 5-day increase of 11.37%, a 20-day increase of 9.01%, and a 60-day increase of 51.94% [1] - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent appearance on February 19, where it recorded a net buy of -47.3628 million yuan [1] Group 2 - Aobo Zhiguang Technology Group Co., Ltd. was established on January 18, 2013, and went public on July 7, 2022, focusing on the design, research and development, production, and sales of 3D visual perception products [2] - The company's main business revenue composition includes 61.83% from consumer-grade application devices, 31.35% from 3D visual sensors, 4.21% from other sources, and 2.60% from industrial-grade application devices [2] - As of June 30, 2025, Aobo Zhiguang achieved an operating income of 435 million yuan, representing a year-on-year growth of 104.14%, and a net profit attributable to shareholders of 60.1901 million yuan, reflecting a year-on-year increase of 212.77% [2] Group 3 - As of June 30, 2025, the top ten circulating shareholders of Aobo Zhiguang include XQH Run Mixed A, holding 4.974 million shares, a decrease of 1.2779 million shares from the previous period [3] - Huaxia Zhongzheng Robot ETF ranks as the seventh largest circulating shareholder, holding 4.4781 million shares, an increase of 800,400 shares from the previous period [3] - XQH Yi Mixed A is the tenth largest circulating shareholder, holding 2.4269 million shares, a decrease of 897,000 shares from the previous period [3]

Group 1 - The first national 3D printing drug production license has been issued in Nanjing, marking a significant step in the development and industrialization of 3D printing technology in pharmaceuticals [2] - The licensed entity, Nanjing SanDieJi Pharmaceutical Technology Co., has a production capacity of 300 million 3D printed drug pieces annually, making it the largest commercial production base for 3D printed drugs globally [2] - 3D printing technology offers advantages over traditional pharmaceutical manufacturing, including complex drug structure design, digital drug development, precise drug delivery, and intelligent manufacturing [2] Group 2 - The 3D printing market in China is projected to reach approximately 423 billion yuan in 2024 and is expected to exceed 450 billion yuan by 2025, driven by the increasing application of 3D printing products and the release of pent-up demand for 3D printing equipment [3] - The application fields of 3D printing are expanding, covering industries such as aerospace, automotive, biomedical, construction, and consumer goods, with rapid growth in the consumer electronics sector [3] Group 3 - Seven 3D printing concept stocks have been frequently researched by institutions, with notable companies including Dazong Laser, Aobi Zhongguang-UW, and Yuedan New Materials, among others [5] - The average increase in the stock prices of 3D printing concept stocks this year is 37.05%, with Zhongzhou Special Materials leading with a 192% increase [5][6] - Companies like Aidi Te and Huazhu High-Tech are actively involved in the 3D printing sector, with Aidi Te having launched multiple 3D printers and Huazhu High-Tech developing its own 3D printing equipment and materials [4][5] Group 4 - Xie Chuang Data (300857) has seen its stock price rise significantly, reaching a market value of 44.303 billion yuan, with a maximum increase of over 11 times compared to its three-year low [7] - The company reported a revenue of 4.944 billion yuan in the first half of the year, a year-on-year increase of 38.18%, with a net profit of 432 million yuan, reflecting a growth of 20.76% [7]

Core Insights - Jiangsu Province has issued the first national drug production license utilizing 3D printing technology, marking a significant advancement in the research and industrialization of 3D printed pharmaceuticals in China [1] - The confidence of pharmaceutical companies in 3D printing technology is greatly encouraged by this development [1] Group 1: Market Performance - As of September 10, 2023, 3D printing concept stocks have seen an average increase of 37.05% this year [1] - Zhongzhou Special Materials has the highest increase at 192%, followed by Huazhu High-Tech with an increase of 111.02% [1] Group 2: Institutional Research - Seven 3D printing concept stocks have been investigated by institutions 10 times or more this year, including Dazhu Laser, Aobi Zhongguang-UW, and others [1] - Dazhu Laser leads with 72 institutional investigations, while Aobi Zhongguang-UW has been investigated 21 times [2]

9月10日，奥比中光盘中上涨2.00%，截至13:00，报87.13元/股，成交5.83亿元，换手率2.33%，总市值 349.48亿元。 责任编辑：小浪快报 资料显示，奥比中光科技集团股份有限公司位于广东省深圳市南山区西丽街道松坪山社区高新北一道88 号奥比科技大厦，成立日期2013年1月18日，上市日期2022年7月7日，公司主营业务涉及3D视觉感知产 品的设计、研发、生产和销售。主营业务收入构成为：消费级应用设备61.83%，3D视觉传感器 31.35%，其他4.21%，工业级应用设备2.60%。 奥比中光所属申万行业为：电子-光学光电子-光学元件。所属概念板块包括：空中成像、空间计算、3D 打印、机器视觉、人形机器人等。 截至6月30日，奥比中光股东户数2.00万，较上期增加1.15%；人均流通股12885股，较上期减少0.71%。 2025年1月-6月，奥比中光实现营业收入4.35亿元，同比增长104.14%；归母净利润6019.01万元，同比增 长212.77%。 资金流向方面，主力资金净流出4524.79万元，特大单买入2942.84万元，占比5.05%，卖出4283.78万 元，占比7.35% ...

（原标题：奥比中光-U大宗交易成交2.47万股 成交额201.13万元） 奥比中光-U9月5日大宗交易平台出现一笔成交，成交量2.47万股，成交金额201.13万元，大宗交易成交 价为81.43元。该笔交易的买方营业部为中信证券股份有限公司上海分公司，卖方营业部为中信证券华 南股份有限公司佛山分公司。 两融数据显示，该股最新融资余额为7.89亿元，近5日增加1011.31万元，增幅为1.30%。（数据宝） 9月5日奥比中光-U大宗交易一览 | 成交量 | 成交金 | 成交价 | 相对当日 | | | | --- | --- | --- | --- | --- | --- | | （万 | 额 | 格 | 收盘折溢 | 买方营业部 | 卖方营业部 | | 股） | （万 | （元） | 价 | | | | | 元） | | （%） | | | | 2.47 | 201.13 | 81.43 | 0.00 | 中信证券股份有限公司上海分 | 中信证券华南股份有限公司佛山分 | | | | | | 公司 | 公司 | 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 证券时报•数据宝统计显示，奥比中光- ...

9月5日，奥比中光大宗交易成交2.47万股，成交额201.13万元，占当日总成交额的0.18%，成交价81.43 元，较市场收盘价81.43元持平。 | 025-09-05 | 奥比中元 | 688322 | 81.43 | 201.13 | 2.47 | 中信证券股份有限 | 中信证券华南股份 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 · · 证券简称 | | 蓬券代码。 | 成交价(元) 成交金额[万元] 成交量(*) 莫入营业部 | | | 公司上海分公司 | 美出营业服 有限公司佛山分公 | 是否为专场 | | ...